DGCI approved Cipla to import Moderna’s COVID-19 vaccine for emergency use in India. Moderna becomes the fourth vaccine after Covishield, Covaxin, and Sputnik.
Moderna is one of the two vaccines received by 120 million Americans and so far no major repercussions have been identified. Moderna is said to be 90% effective against COVID-19.
As for Pfizer, the company’s CEO Albert Bourla issued a statement about the progress of approval in India which is said to be in its final stages. The rollout for the foreign vaccines had been stalled over the conditions of foreign countries to waive their right to indemnify from liabilities raised due to an adverse effect of the vaccine.